Literature DB >> 9259301

Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants.

A Verrotti1, S Domizio, B Angelozzi, G Sabatino, G Morgese, F Chiarelli.   

Abstract

OBJECTIVE: To assess the effect of long-term treatment of phenobarbital, carbamazepine and sodium valproate on serum lipids and lipoproteins in epileptic children.
METHODOLOGY: One hundred and fourteen (55 male, 59 female) children and adolescents suffering from various types of epilepsy who received different antiepileptic drugs were studied. The patients were subdivided into three groups according to their therapy: (i) carbamazepine (35 patients); (ii) phenobarbital (34 patients); and (iii) sodium valproate (45 patients). One-hundred healthy sex- and age-matched children served as controls. Lipids and lipoprotein profile were evaluated before the beginning of the anticonvulsant therapy and after at least 2.5 years. In the patients receiving phenobarbital, we re-evaluated 12 children (seven male, five female) at the end of therapy.
RESULTS: The children receiving phenobarbital showed high levels of serum total cholesterol and low-density lipoprotein (LDL) cholesterol and low levels of triglycerides, while children treated with carbamazepine had high levels of total cholesterol, triglycerides, LDL and high-density lipoprotein (HDL) cholesterol. Children treated with valproate had low triglycerides and LDL cholesterol levels with high levels of HDL cholesterol. The patients treated with phenobarbital showed a normalization of all parameters after the end of therapy.
CONCLUSIONS: Anticonvulsant drugs significantly modify serum lipids and lipoproteins in epileptic children. The changes due to phenobarbital seem to be transient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259301     DOI: 10.1111/j.1440-1754.1997.tb01588.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  9 in total

1.  Serum cholesterol in cerebral malignancies.

Authors:  P Grieb; M S Ryba; J Jagielski; W Gackowski; P Paczkowski; S J Chrapusta
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Plaques on the wall: inducing anticonvulsant use and atherogenesis.

Authors:  Scott Mintzer
Journal:  Epilepsy Curr       Date:  2012-11       Impact factor: 7.500

3.  Antiepileptic drugs and markers of vascular risk.

Authors:  Carla Lopinto-Khoury; Scott Mintzer
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

Review 4.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Evaluation of Effect of Antiepileptic Drugs on Serum Lipid Profile among Young Adults with Epilepsy in a Tertiary Care Hospital in Pondicherry.

Authors:  K Manimekalai; B Visakan; Kartik J Salwe; S Murugesan
Journal:  J Clin Diagn Res       Date:  2014-08-20

6.  Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein.

Authors:  Scott Mintzer; Rachael Miller; Krunal Shah; Inna Chervoneva; Maromi Nei; Christopher Skidmore; Michael R Sperling
Journal:  Epilepsy Behav       Date:  2016-04-10       Impact factor: 2.937

7.  Serum level of homocysteine, folate and vitamin-B12 in epileptic patients under carbamazepine and sodium valproate treatment: a systematic review and meta-analysis.

Authors:  Fazel Gorjipour; Yasin Asadi; Nushin K Osguei; Marjan Effatkhah; Ali Samadikuchaksaraei
Journal:  Iran Red Crescent Med J       Date:  2013-03-05       Impact factor: 0.611

8.  Parameters of metabolic syndrome in Indian children with epilepsy on valproate or phenytoin monotherapy.

Authors:  Aditi Dhir; Suvasini Sharma; Puneet Jain; Bhanu K Bhakhri; Satinder Aneja
Journal:  J Pediatr Neurosci       Date:  2015 Jul-Sep

Review 9.  Epilepsy management in pregnant HIV+ women in sub-Saharan Africa, clinical aspects to consider: a scoping review.

Authors:  Sonia Menon; Lenka Benova; Hillary Mabeya
Journal:  BMC Med       Date:  2020-11-17       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.